ENGINEERED PROBIOTICS AND THE APPLICATIONS THEREOF

Abstract: a genetically engineered strain of nissle 1917 (ecn) with a modified genome designed to enhance the production of short-chain fatty acids (scfas) is provided. the engineered genome includes the atob gene from k-12, responsible for encoding acetyl-coa acetyltransferase, a crt-bcd-etfa-etfb-bhbd gene cluster from e. that encodes enzymes involved in the synthesis of scfas, specifically enoyl-coa hydratase, butyryl-coa dehydrogenase, and electron transfer flavoproteins, and the ptb-buk gene from , which encodes phosphotransbutyrylase and butyrate kinase. additionally, key genes associated with competing metabolic pathways—ldha, frdabcd, adhe, acka, and pta—are deleted to optimize scfa production, particularly butyrate. this strain is intended for use in therapeutic applications where enhanced scfa production is beneficial, such as in the treatment of coronary heart disease.

Inventor(s): Quynh Hoa PHAM, Chi Kong LAU, Kiwon BAN, Thi Van Anh BUI

CPC Classification: A61K35/741 (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms ; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles ; soap compositions ))

Search for rejections for patent application number 20250161372